Skip to main content
SpringerLink
Log in

High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma

  • Lymphomas (PA Hamlin, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

High-dose chemotherapy followed by autologous hematopoietic stem cell transplant (HDT/ASCT) can improve survival in patients with lymphoma. Limited experience is available on the safety and efficacy of HDT/ASCT in elderly patients. In this article, we review the published data on the role of HDT/ASCT in management of lymphoma in older patients. Based on available data, evaluation of comorbidities, functional status, and comprehensive geriatric assessment (CGA) will help identify those who can benefit most from this intervention. Prospective clinical trials focusing on HDT/ASCT in older patients with lymphoma are needed to establish optimal management protocols in this select population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27:2758–65.

    Article  PubMed  Google Scholar 

  2. Mc FW, Granville NB, Dameshek W. Autologous bone marrow infusion as an adjunct in therapy of malignant disease. Blood. 1959;14:503–21.

    Google Scholar 

  3. Clifford P, Clift RA, Duff JK. Nitrogen-mustard therapy combined with autologous marrow infusion. Lancet. 1961;1:687–90.

    Article  CAS  PubMed  Google Scholar 

  4. Pegg DE. A quantitative study of bone marrow grafting: implications for human bone marrow infusion. Br J Cancer. 1962;16:400–16.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Kurnick NB. Autologous and isologous bone marrow storage and infusion in the treatment of myelo-suppresson. Transfusion. 1962;2:178–87.

    Article  CAS  PubMed  Google Scholar 

  6. Appelbaum FR, Herzig GP, Ziegler JL, et al. Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood. 1978;52:85–95.

    CAS  PubMed  Google Scholar 

  7. Appelbaum FR, Deisseroth AB, Graw Jr RG, et al. Prolonged complete remission following high dose chemotherapy of Burkitt’s lymphoma in relapse. Cancer. 1978;41:1059–63.

    Article  CAS  PubMed  Google Scholar 

  8. Phillips GL, Wolff SN, Herzig RH, et al. Treatment of progressive Hodgkin’s disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood. 1989;73:2086–92.

    CAS  PubMed  Google Scholar 

  9. Carella AM, Santini G, Santoro A, et al. Massive chemotherapy with non-frozen autologous bone marrow transplantation in 13 cases of refractory Hodgkin’s disease. Eur J Cancer Clin Oncol. 1985;21:607–13.

    Article  CAS  PubMed  Google Scholar 

  10. Jagannath S, Dicke KA, Armitage JO, et al. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin’s disease. Ann Intern Med. 1986;104:163–8.

    Article  CAS  PubMed  Google Scholar 

  11. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341:1051–4.

    Article  CAS  PubMed  Google Scholar 

  12. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359:2065–71.

    Article  CAS  PubMed  Google Scholar 

  13. Buadi FK, Micallef IN, Ansell SM, et al. Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2006;37:1017–22.

    Article  CAS  PubMed  Google Scholar 

  14. Lazarus HM, Carreras J, Boudreau C, et al. Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2008;14:1323–33.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–5.

    Article  CAS  PubMed  Google Scholar 

  16. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998;16:3803–9.

    CAS  PubMed  Google Scholar 

  17. Thieblemont C, Antal D, Lacotte-Thierry L, et al. Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer. 2005;104:1434–41.

    Article  CAS  PubMed  Google Scholar 

  18. Ritchie DS, Seymour JF, Grigg AP, et al. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol. 2007;86:101–5.

    Article  CAS  PubMed  Google Scholar 

  19. LaCasce AS, Vandergrift JL, Rodriguez MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 2012;119:2093–9.

    Article  CAS  PubMed  Google Scholar 

  20. Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112:2687–93.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Geisler CH, Kolstad A, Laurell A, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012;158:355–62.

    Article  CAS  PubMed  Google Scholar 

  22. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105:2677–84.

    Article  CAS  PubMed  Google Scholar 

  23. d’Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–9.

    Article  PubMed  Google Scholar 

  24. Feyler S, Prince HM, Pearce R, et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant. 2007;40:443–50.

    Article  CAS  PubMed  Google Scholar 

  25. Jantunen E, Wiklund T, Juvonen E, et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant. 2004;33:405–10.

    Article  CAS  PubMed  Google Scholar 

  26. Rodriguez J, Conde E, Gutierrez A, et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol. 2007;18:652–7.

    Article  CAS  PubMed  Google Scholar 

  27. McCarthy Jr PL, Hahn T, Hassebroek A, et al. Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995–2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. Biol Blood Marrow Transplant. 2013;19:1116–23.

    Article  PubMed Central  PubMed  Google Scholar 

  28. Piccirillo JF, Vlahiotis A, Barrett LB, et al. The changing prevalence of comorbidity across the age spectrum. Crit Rev Oncol Hematol. 2008;67:124–32.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Brice P, Bouabdallah R, Moreau P, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry. Societe Francaise de Greffe de Moelle. Bone Marrow Transplant. 1997;20:21–6.

    Article  CAS  PubMed  Google Scholar 

  30. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97:616–23.

    Article  CAS  PubMed  Google Scholar 

  31. Sureda A, Schmitz N. Role of allogeneic stem cell transplantation in relapsed or refractory Hodgkin’s disease. Ann Oncol. 2002;13 Suppl 1:128–32.

    Article  PubMed  Google Scholar 

  32. Jabbour E, Hosing C, Ayers G, et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer. 2007;109:2481–9.

    Article  PubMed  Google Scholar 

  33. Smeltzer JP, Cashen AF, Zhang Q, et al. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:1646–52.

    Article  PubMed Central  PubMed  Google Scholar 

  34. Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012;119:1665–70.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Derenzini E, Musuraca G, Fanti S, et al. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Cancer. 2008;113:2496–503.

    Article  PubMed  Google Scholar 

  36. Dickinson M, Hoyt R, Roberts AW, et al. Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. Br J Haematol. 2010;150:39–45.

    PubMed  Google Scholar 

  37. Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987–94.

    Article  Google Scholar 

  38. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–65.

    Article  CAS  PubMed  Google Scholar 

  39. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558–65.

    Article  CAS  PubMed  Google Scholar 

  40. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–61.

    Article  CAS  PubMed  Google Scholar 

  41. Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–42.

    Article  CAS  PubMed  Google Scholar 

  42. Advani RH, Chen H, Habermann TM, et al. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Br J Haematol. 2010;151:143–51.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Hamlin PA, Zelenetz AD, Kewalramani T, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2003;102:1989–96.

    Article  CAS  PubMed  Google Scholar 

  44. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184–90.

    Article  PubMed Central  PubMed  Google Scholar 

  45. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Sorror ML, Storb RF, Sandmaier BM, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014;32:3249–56.

    Article  PubMed  Google Scholar 

  47. Plattel WJ, Kluin-Nelemans HC, de Bock GH, et al. Prognostic value of comorbidity for auto-SCT eligibility and outcome in relapsed or refractory aggressive non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2011;46:827–34.

    Article  CAS  PubMed  Google Scholar 

  48. Tucci A, Ferrari S, Bottelli C, et al. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer. 2009;115:4547–53.

    Article  PubMed  Google Scholar 

  49. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29:3457–65.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118:3377–86.

    Article  PubMed  Google Scholar 

  51. Fratino L, Rupolo M, Mazzuccato M, et al. Autologus stem cell transplatation as a care option in elderly patients. A review. Anticancer Agents Med Chem. 2013;13:1419–29.

    Article  CAS  PubMed  Google Scholar 

  52. Demirer T, Petersen FB, Bensinger WI, et al. Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia. Bone Marrow Transplant. 1996;18:29–34.

    CAS  PubMed  Google Scholar 

  53. Tomblyn M, Burns LJ, Blazar B, et al. Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma. Bone Marrow Transplant. 2007;40:111–8.

    Article  CAS  PubMed  Google Scholar 

  54. Stadtmauer EA, Schneider CJ, Silberstein LE. Peripheral blood progenitor cell generation and harvesting. Semin Oncol. 1995;22:291–300.

    CAS  PubMed  Google Scholar 

  55. Kanteti R, Miller K, McCann J, et al. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin’s lymphoma and Hodgkin’s disease: a clinical and molecular analysis. Bone Marrow Transplant. 1999;24:473–81.

    Article  CAS  PubMed  Google Scholar 

  56. Vose JM, Sharp G, Chan WC, et al. Autologous transplantation for aggressive non-Hodgkin’s lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol. 2002;20:2344–52.

    Article  PubMed  Google Scholar 

  57. Steidl U, Fenk R, Bruns I, et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant. 2005;35:33–6.

    Article  CAS  PubMed  Google Scholar 

  58. Bruns I, Steidl U, Kronenwett R, et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion. 2006;46:180–5.

    Article  CAS  PubMed  Google Scholar 

  59. Russell N, Mesters R, Schubert J, et al. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin’s lymphoma receiving chemotherapy. Haematologica. 2008;93:405–12.

    Article  CAS  PubMed  Google Scholar 

  60. Micallef IN, Stiff PJ, Stadtmauer EA, et al. Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients >/=60 and <60 years of age with non-Hodgkin’s lymphoma or multiple myeloma. Am J Hematol. 2013;88:1017–23.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  61. Geiger H, Denkinger M, Schirmbeck R. Hematopoietic stem cell aging. Curr Opin Immunol. 2014;29:86–92.

    Article  CAS  PubMed  Google Scholar 

  62. Tempescul A, Ianotto JC, Hardy E, et al. Peripheral blood stem cell collection in elderly patients. Ann Hematol. 2010;89:317–21.

    Article  PubMed  Google Scholar 

  63. Woolthuis CM, Mariani N, Verkaik-Schakel RN, et al. Aging impairs long-term hematopoietic regeneration after autologous stem cell transplantation. Biol Blood Marrow Transplant. 2014;20:865–71.

    Article  PubMed  Google Scholar 

  64. Mileshkin LR, Seymour JF, Wolf MM, et al. Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leuk Lymphoma. 2005;46:1575–9.

    Article  CAS  PubMed  Google Scholar 

  65. Wildes TM, Augustin KM, Sempek D, et al. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14:840–6.

    Article  CAS  PubMed  Google Scholar 

  66. Jantunen E, Itala M, Juvonen E, et al. Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin’s lymphoma: a nation-wide analysis. Bone Marrow Transplant. 2006;37:367–72.

    Article  CAS  PubMed  Google Scholar 

  67. Puig N, Pintilie M, Seshadri T, et al. High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin’s lymphoma. Bone Marrow Transplant. 2011;46:1339–44.

    Article  CAS  PubMed  Google Scholar 

  68. Pecego R, Hill R, Appelbaum FR, et al. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation. 1986;42:515–7.

    Article  CAS  PubMed  Google Scholar 

  69. Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case–control study. Blood. 2003;101:2015–23.

    Article  CAS  PubMed  Google Scholar 

  70. Friedberg JW, Neuberg D, Stone RM, et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17:3128–35.

    CAS  PubMed  Google Scholar 

  71. Puig N, de la Rubia J, Remigia MJ, et al. Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma. 2006;47:1488–94.

    Article  PubMed  Google Scholar 

  72. William BM, Loberiza Jr FR, Whalen V, et al. Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2013;13:417–23.

    Article  PubMed  Google Scholar 

  73. Mounier N, Gisselbrecht C. Conditioning regimens before transplantation in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol. 1998;9 Suppl 1:S15–21.

    Article  PubMed  Google Scholar 

  74. Yusuf RZ, Dey B, Yeap BY, et al. Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2009;43:37–42.

    Article  CAS  PubMed  Google Scholar 

  75. Gopal AK, Rajendran JG, Gooley TA, et al. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol. 2007;25:1396–402.

    Article  PubMed  Google Scholar 

  76. Gopal AK, Gooley TA, Rajendran JG, et al. Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age >/= 60 years with B cell lymphoma. Biol Blood Marrow Transplant. 2014;20:770–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  77. Stamatoullas A, Fruchart C, Khalfallah S, et al. Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age. Bone Marrow Transplant. 1997;19:31–5.

    Article  CAS  PubMed  Google Scholar 

  78. Moreau P, Milpied N, Voillat L, et al. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study. Bone Marrow Transplant. 1998;21:1193–6.

    Article  CAS  PubMed  Google Scholar 

  79. Leger CS, Bredeson C, Kearns B, et al. Autologous blood and marrow transplantation in patients 60 years and older. Biol Blood Marrow Transplant. 2000;6:204–10.

    Article  CAS  PubMed  Google Scholar 

  80. Jantunen E, Mahlamaki E, Nousiainen T. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin’s lymphoma: comparison with patients <60 years treated within the same protocol. Bone Marrow Transplant. 2000;26:737–41.

    Article  CAS  PubMed  Google Scholar 

  81. Gopal AK, Gooley TA, Golden JB, et al. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin’s lymphoma in adults 60 years of age and older. Bone Marrow Transplant. 2001;27:593–9.

    Article  CAS  PubMed  Google Scholar 

  82. Olivieri A, Capelli D, Montanari M, et al. Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience. Bone Marrow Transplant. 2001;27:1189–95.

    Article  CAS  PubMed  Google Scholar 

  83. Zallio F, Cuttica A, Caracciolo D, et al. Feasibility of peripheral blood progenitor cell mobilization and harvest to support chemotherapy intensification in elderly patients with poor prognosis: non-Hodgkin’s lymphoma. Ann Hematol. 2002;81:448–53.

    Article  CAS  PubMed  Google Scholar 

  84. Bitran JD, Klein L, Link D, et al. High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma. Biol Blood Marrow Transplant. 2003;9:383–8.

    Article  PubMed  Google Scholar 

  85. Magagnoli M, Castagna L, Balzarotti M, et al. Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin’s lymphoma: survey from a single institution. Am J Hematol. 2003;73:267–72.

    Article  CAS  PubMed  Google Scholar 

  86. Villela L, Sureda A, Canals C, et al. Low transplant related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation. Haematologica. 2003;88:300–5.

    PubMed  Google Scholar 

  87. Hosing C, Saliba RM, Okoroji GJ, et al. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin’s lymphoma in patients >65 years of age. Ann Oncol. 2008;19:1166–71.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  88. Jantunen E, Canals C, Rambaldi A, et al. Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica. 2008;93:1837–42.

    Article  PubMed  Google Scholar 

  89. Andorsky DJ, Cohen M, Naeim A, et al. Outcomes of auto-SCT for lymphoma in subjects aged 70 years and over. Bone Marrow Transplant. 2011;46:1219–25.

    Article  CAS  PubMed  Google Scholar 

  90. Elstrom RL, Martin P, Hurtado Rua S, et al. Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. Am J Hematol. 2012;87:433–5.

    Article  PubMed  Google Scholar 

  91. Jantunen E, Canals C, Attal M, et al. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol. 2012;23:166–71. A large study from European Registry analysing transplant outcomes in elderly patients.

    Article  CAS  PubMed  Google Scholar 

  92. Chihara D, Izutsu K, Kondo E, et al. High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study. Biol Blood Marrow Transplant. 2014;20:684–9. A large study of Japanese Transplant Registry on outcomes of autologous transplant in elderly patients with lymphoma.

    Article  CAS  PubMed  Google Scholar 

  93. Dahi PB, Tamari R, Devlin SM, et al. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014;20:2004–9. A large single center study showing feasibility of transplant in select elderly population.

    Article  PubMed  Google Scholar 

  94. Frosch Z, Luskin MR, Landsburg DJ, et al. R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2015;15:92–7.

    Article  PubMed  Google Scholar 

  95. Martin N, Borchiellini D, Coso D, et al. High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. Leuk Lymphoma 2015:1–9.

  96. Sweetenham JW, Pearce R, Philip T, et al. High-dose therapy and autologous bone marrow transplantation for intermediate and high grade non-Hodgkin’s lymphoma in patients aged 55 years and over: results from the European Group for Bone Marrow Transplantation. The EBMT Lymphoma Working Party. Bone Marrow Transplant. 1994;14:981–7.

    CAS  PubMed  Google Scholar 

  97. Miller CB, Piantadosi S, Vogelsang GB, et al. Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant. J Clin Oncol. 1996;14:1327–32.

    CAS  PubMed  Google Scholar 

  98. Kusnierz-Glaz CR, Schlegel PG, Wong RM, et al. Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. J Clin Oncol. 1997;15:18–25.

    CAS  PubMed  Google Scholar 

  99. Wildes TM, Stirewalt DL, Medeiros B, et al. Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic. J Natl Compr Canc Netw. 2014;12:128–36. A comprehensive review of autologous and allogeneic stem cell transplant in elderly.

    PubMed Central  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Oscar B. Lahoud, Craig S. Sauter, Paul A. Hamlin, and Parastoo Bahrami Dahi declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author Contributions

O.B.L, C.S.S, P.A.H, and P.B.D. interpreted the data and wrote the manuscript.

Author information

Authors and Affiliations

  1. Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Oscar B. Lahoud, Craig S. Sauter & Parastoo Bahrami Dahi

  2. Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Paul A. Hamlin

  3. Department of Medicine, Weill Cornell Medical College, New York, NY, USA

    Craig S. Sauter, Paul A. Hamlin & Parastoo Bahrami Dahi

Authors
  1. Oscar B. Lahoud
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Craig S. Sauter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul A. Hamlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Parastoo Bahrami Dahi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Parastoo Bahrami Dahi.

Additional information

This article is part of the Topical Collection on Lymphomas

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lahoud, O.B., Sauter, C.S., Hamlin, P.A. et al. High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma. Curr Oncol Rep 17, 42 (2015). https://doi.org/10.1007/s11912-015-0465-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-015-0465-x

Keywords

Search

Navigation